2.36
-18.06%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cypherpunk Technologies
From its filings with the US Securities and Exchange Commission
Cypherpunk Technologies is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CYPH. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2021, it reported revenue of $1.5m.
We were incorporated in the state of Delaware on January 3, 2011. Our wholly owned subsidiaries as of December 31, 2025 include HealthCare Pharmaceuticals Pty Ltd. (“HCP Australia”), Leap Securities Corp., Flame Biosciences LLC, and Leap Therapeutics, Inc. (“Leap”).
Prior to October 2025, we devoted substantially all of our resources to development efforts related to biomarker-targeted antibody therapies designed to treat patients with cancer. Our clinical stage program is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1, for the treatment of colorectal cancer patients. We also have a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.
In October 2025, we announced a $58.88 million private placement, led by Winklevoss Capital, and the intent to initiate a digital asset treasury strategy. Immediately following the financing, we initiated a strategy to deploy a portion of our capital raised that is not required to provide working capital for our ongoing operations to accumulate digital assets, focused on Zcash. Zcash is a protocol and blockchain network of connected devices all over the world, working together to validate transactions and maintain the Zcash ledger. ZEC is the monetary unit, or coin, of Zcash. Zcash allows for transactional privacy, providing users with options for fully shielded transactions in which the sender, recipient, and amount are encrypted.
Quoted from its 10-K, filed 16 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 Jan 2017
- Employees
- 6
- Website
- leaptx.com ↗
- Head office
- 47 THORNDIKE STREET, CAMBRIDGE, MA, 02142
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Christopher MirabelliChairman of the Board, since 2011$744,179
- Mr. Douglas OnsiPresident, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director, since 2011$1.5m
- Dr. Jason BaumChief Scientific Officer
- Ms. Christine GranfieldVice President, Head - Regulatory Affairs and Quality
- Mr. Mark O'MahonyChief Manufacturing Officer
- Dr. Cynthia SirardChief Medical Officer$1.1m
- Dr. Thomas DietzLead Independent Director$243,383
- Dr. James CavanaughIndependent Director$163,055
- Dr. William LiIndependent Director$158,055
- Dr. Joseph LoscalzoIndependent Director$148,555
- Ms. Patricia MartinIndependent Director$159,122
- Mr. Nissim MashiachIndependent Director$153,484
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is a clinical stage biopharmaceutical company focused on developing novel cancer therapies.
- Headquartered in Cambridge, Massachusetts with a small team of 6 employees.
- IPO occurred on 2017-01-24, indicating established market presence.
Weaknesses
- The company has only 6 employees, indicating limited operational capacity.
- The source description mentions 24 employees, conflicting with the provided 6 employees.
- The company's programs are still in clinical stage, indicating early development phase.
Opportunities
- Monoclonal antibody programs like DKN-01 and TRX518 target key cancer pathways for potential market opportunities.
- Focus on immune system activation mechanisms could align with growing cancer treatment trends.
- IPO in 2017 provides a foundation for future capital raising and expansion.
Threats
- Clinical stage development carries high risk of failure in drug development.
- Conflicting employee count (6 vs 24) may indicate unreliable internal data reporting.
- Biotechnology sector is highly competitive with significant R&D investment requirements.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.